Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPORADIC: cemiplimab added to sequential hypofractionated chemoradiotherapy in unfit or elderly unresectable stage III NSCLC
2024-517316-29-00Phase 2Authorised
- Sponsor
- IFCT
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cemiplimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by IFCT. Primary endpoint: Progression-free survival. Planned start Nov 2025; status: authorised.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-517316-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517316-29-00.